

24 July

2006



08002203

Securities and Exchange Commission
Judiciary Plaza,
450 Fifth Street,
Washington DC 20549

SEC
Mail Processing
Section

APR 28 2008

Washington, DC
105

SUPPL

Re: Bionomics Limited - File number 82-34682

Please see attached provided pursuant to Section 12g3-2(b) file number 82-34682.

Yours sincerely

Stephen Birrell
CFO & Company Secretary

PROCESSED
E MAY 06 2008
THOMSON REUTERS

Appendix 4C

Quarterly report for entities admitted on the basis of commitments

Introduced 31/3/2000. Amended 30/9/2001

Name of entity

BIONOMICS LIMITED

ABN

53 075 582 740

Quarter ended ("current quarter")

30-Jun-06**Consolidated statement of cash flows**

	Current quarter \$A'000	Year to date (12 months) \$A'000
Cash flows related to operating activities		
1.1	309	1,803
1.2		
(a)	(256)	(1,403)
(b)	0	(42)
(c)	(1,506)	(5,897)
(d)	(11)	(33)
(e)	(183)	(1,187)
1.3	0	0
1.4	91	309
1.5	(77)	(319)
1.6	0	0
1.7	1	4
Government Grants	744	2,247
Rent Received	57	188
EMDG	30	130
Net operating cash flows	(801)	(4,200)
1.8	(801)	(4,200)
Cash flows related to investing activities		
1.9		
(a)	0	(93)
(b)	0	0
(c)	0	0
(d)	0	(30)
(e)	0	0

+ See chapter 19 for defined terms

	Current quarter \$A'000	Year to date (12 months) \$A'000
1.10 Proceeds from disposal of:		
(a) businesses (item 5)	0	0
(b) equity investment	0	0
(c) intellectual property	0	0
(d) physical non-current assets	0	0
(e) other non-current assets	0	0
1.11 Loans to other entities	0	0
1.12 Loans repaid by other entities	0	0
1.13 Other (Iliad bank accounts)	0	397
Net investing cash flows	0	274
1.14 Total operating and investing cash flows	(801)	(3,926)
Cash flows related to financing activities		
1.15 Proceeds from issues of shares, options, etc.	0	0
1.16 Proceeds from sale of forfeited shares	0	0
1.17 Proceeds from borrowings	0	0
1.18 Repayment of borrowings	(91)	(353)
1.19 Dividends paid	0	0
1.20 Other (capital raising costs)	0	0
Net financing cash flows	(91)	(353)
Net increase (decrease) in cash held	(892)	(4,279)
1.21 Cash at beginning of quarter/year to date	5,617	9,004
1.22 Exchange rate adjustments to item 1.20		
1.23 Cash at end of quarter	4,725	4,725

Payments to directors of the entity and associates of the directors

Payments to related entities of the entity and associates of the related entities

	Current quarter \$A'000
1.24 Aggregate amount of payments to the parties included in item 1.2	(112)
1.25 Aggregate amount of loans to the parties included in item 1.11	0

1.26 Explanation necessary for an understanding of the transactions

Consists of remuneration paid to directors including remuneration paid to the Chief Executive Officer and Managing Director.

+ See chapter 19 for defined terms

Non-cash financing and investing activities

- 2.1 Details of financing and investing transactions which have had a material effect on consolidated assets and liabilities but did not involve cash flows

N/A

- 2.2 Details of outlays made by other entities to establish or increase their share in businesses in which the reporting entity has an interest

N/A

Financing facilities available

Add notes as necessary for an understanding of the position. (See AASB 1026 paragraph 12.2).

	Amount available \$A'000	Amount used \$A'000
3.1 Loan facilities	0	0
3.2 Credit standby arrangements	0	0

Explanation necessary for an understanding of financing facilities available

[Empty box for explanation]

Reconciliation of cash

Reconciliation of cash at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts is as follows.

	Current quarter \$A'000	Previous quarter \$A'000
4.1 Cash on hand and at bank	738	1,045
4.2 Deposits at call	3,987	4,572
4.3 Bank overdraft		
4.4 Other (provide details)		
Total: cash at end of quarter (item 1.22)	4,725	5,617

+ See chapter 19 for defined terms

Acquisitions and disposals of business entities

	Acquisitions \$A'000 (Item 1.9(a))	Disposals (Item 1.10(a))
5.1 Name of entity		
5.2 Place of incorporation or registration		
5.3 Consideration for acquisition or disposal		
5.4 Total net assets		
5.5 Nature of business		

Compliance statement

1 This statement has been prepared under accounting policies, which comply with accounting standards as defined in the Corporations Act (except to the extent that information is not required because of note 2) or other standards acceptable to ASX.

2 This statement does ~~does not~~ *(delete one)* give a true and fair view of the matters disclosed.

Sign here: Date:
(CEO & Managing Director)

Print name: DEBORAH RATHJEN

Notes

1 The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity wanting to disclose additional information is encouraged to do so, in a note or notes attached to this report.

2 The definitions in, and provisions of, *AASB 1026: Statement of Cash Flows* apply to this report except for the paragraphs of the Standard set out below.

- 6.2 - reconciliation of cash flows arising from operating activities to operating profit or loss
- 9.2 - itemised disclosure relating to acquisitions
- 9.4 - itemised disclosure relating to disposals
- 12.1(a) - policy for classification of cash items
- 12.3 - disclosure of restrictions on use of cash
- 13.1 - comparative information

3 **Accounting Standards.** ASX will accept, for example, the use of International Accounting Standards for foreign entities. If the standards used do not address a topic, the Australian standard on that topic (if any) must be complied with.

+ See chapter 19 for defined terms

22 September 2006

Securities and Exchange Commission
Judiciary Plaza,
450 Fifth Street,
Washington DC 20549

SEC
Mail Processing
Section
APR 28 2008
Washington, DC
105

Re: Bionomics Limited - File number 82-34682

Please see attached provided pursuant to Section 12g3-2(b) file number 82-34682.

Yours sincerely



Stephen Birrell
CFO & Company Secretary

Appendix 3X

Initial Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity: Bionomics Limited
ABN: 53 075 582 740

We (the entity) give ASX the following information under listing rule 3.19A.1 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Trevor Tappenden
Date of appointment	15 September 2006

Part 1 - Director's relevant interests in securities of which the director is the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Number & class of securities Nil
--

Part 2 - Director's relevant interests in securities of which the director is not the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Name of holder & nature of interest Note: Provide details of the circumstances giving rise to the relevant interest.	Number & class of Securities Nil
--	--

+ See chapter 19 for defined terms.

**Appendix 3X
Initial Director's Interest Notice**

Part 3 – Director's interests in contracts

Detail of contract	
Nature of interest	
Name of registered holder (if issued securities)	
No. and class of securities to which interest relates	Nil

+ See chapter 19 for defined terms.

22 September 2006

Securities and Exchange Commission
Judiciary Plaza,
450 Fifth Street,
Washington DC 20549

SEC
Mail Processing
Section
APR 28 2008
Washington DC
105

Re: Bionomics Limited - File number 82-34682

Please see attached provided pursuant to Section 12g3-2(b) file number 82-34682.

Yours sincerely



Stephen Birrell
CFO & Company Secretary

Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 1/7/96. Origin: Appendix 5. Amended 1/7/98, 1/9/99, 1/7/2000, 30/9/2001, 11/3/2002.

Name of entity

BIONOMICS LIMITED

ABN

53 075 582 740

We (the entity) give ASX the following information.

Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

1 +Class of +securities issued or to be issued

UNLISTED OPTIONS

2 Number of +securities issued or to be issued (if known) or maximum number which may be issued

ONE HUNDRED AND NINETY THREE THOUSAND SEVEN HUNDRED AND FIFTY (193,750)

3 Principal terms of the +securities (eg, if options, exercise price and expiry date; if partly paid +securities, the amount outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion)

EXERCISE PRICE: 16 cents (set in accordance with the terms of the Bionomics ESOP).

EXPIRY DATE: 5 years after the date on which the options became exercisable.

+ See chapter 19 for defined terms.

Appendix 3B
New issue announcement

<p>4 Do the ⁺securities rank equally in all respects from the date of allotment with an existing ⁺class of quoted ⁺securities?</p> <p>If the additional securities do not rank equally, please state:</p> <ul style="list-style-type: none"> • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment 	<p>YES</p>								
<p>5 Issue price or consideration</p>	<p>NIL</p>								
<p>6 Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)</p>	<p>OPTIONS ISSUED TO STAFF UNDER THE BIONOMICS LIMITED EMPLOYEE SHARE OPTION PLAN.</p>								
<p>7 Dates of entering ⁺securities into uncertificated holdings or despatch of certificates</p>	<p>21 SEPTEMBER 2006</p>								
<p>8 Number and ⁺class of all ⁺securities quoted on ASX (including the securities in clause 2 if applicable)</p>	<table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="text-align: left;">Number</th> <th style="text-align: left;">⁺Class</th> </tr> </thead> <tbody> <tr> <td>154,918,432</td> <td>ORDINARY SHARES</td> </tr> <tr> <td>9,795,822</td> <td>OPTIONS EXP. 31-07-07</td> </tr> <tr> <td>31,535,063</td> <td>OPTIONS EXP. 31-01-09</td> </tr> </tbody> </table>	Number	⁺ Class	154,918,432	ORDINARY SHARES	9,795,822	OPTIONS EXP. 31-07-07	31,535,063	OPTIONS EXP. 31-01-09
Number	⁺ Class								
154,918,432	ORDINARY SHARES								
9,795,822	OPTIONS EXP. 31-07-07								
31,535,063	OPTIONS EXP. 31-01-09								

+ See chapter 19 for defined terms.

	Number	+Class
9 Number and +class of all +securities not quoted on ASX (including the securities in clause 2 if applicable)	12,190,333	OPTIONS
10 Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)	NOT APPLICABLE – EARLY STAGE BIOTECHNOLOGY COMPANY	

Part 2 - Bonus issue or pro rata issue

- 11 Is security holder approval required?
- 12 Is the issue renounceable or non-renounceable?
- 13 Ratio in which the +securities will be offered
- 14 +Class of +securities to which the offer relates
- 15 +Record date to determine entitlements
- 16 Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?
- 17 Policy for deciding entitlements in relation to fractions
- 18 Names of countries in which the entity has +security holders who will not be sent new issue documents
Note: Security holders must be told how their entitlements are to be dealt with.
Cross reference: rule 7.7.
- 19 Closing date for receipt of acceptances or renunciations

+ See chapter 19 for defined terms.

Appendix 3B
New issue announcement

- | | | |
|----|---|--|
| 20 | Names of any underwriters | |
| 21 | Amount of any underwriting fee or commission | |
| 22 | Names of any brokers to the issue | |
| 23 | Fee or commission payable to the broker to the issue | |
| 24 | Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of *security holders | |
| 25 | If the issue is contingent on *security holders' approval, the date of the meeting | |
| 26 | Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent to persons entitled | |
| 27 | If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders | |
| 28 | Date rights trading will begin (if applicable) | |
| 29 | Date rights trading will end (if applicable) | |
| 30 | How do *security holders sell their entitlements <i>in full</i> through a broker? | |
| 31 | How do *security holders sell <i>part</i> of their entitlements through a broker and accept for the balance? | |

+ See chapter 19 for defined terms.

- 32 How do +security holders dispose of their entitlements (except by sale through a broker)?
- 33 +Despatch date

Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities

34 Type of securities
(tick one)

(a) Securities described in Part 1

(b) All other securities

Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

Entities that have ticked box 34(a)

Additional securities forming a new class of securities

(If the additional securities do not form a new class, go to 43)

Tick to indicate you are providing the information or documents

- 35 If the +securities are +equity securities, the names of the 20 largest holders of the additional +securities, and the number and percentage of additional +securities held by those holders
- 36 If the +securities are +equity securities, a distribution schedule of the additional +securities setting out the number of holders in the categories
1 - 1,000
1,001 - 5,000
5,001 - 10,000
10,001 - 100,000
100,001 and over
- 37 A copy of any trust deed for the additional +securities

(now go to 43)

+ See chapter 19 for defined terms.

Entities that have ticked box 34(b)

38 Number of securities for which
+quotation is sought

39 Class of +securities for which
quotation is sought

40 Do the +securities rank equally in all
respects from the date of allotment
with an existing +class of quoted
+securities?

If the additional securities do not
rank equally, please state:

- the date from which they do
- the extent to which they
participate for the next dividend,
(in the case of a trust,
distribution) or interest payment
- the extent to which they do not
rank equally, other than in
relation to the next dividend,
distribution or interest payment

41 Reason for request for quotation
now

Example: In the case of restricted securities, end of
restriction period

(if issued upon conversion of
another security, clearly identify that
other security)

Number	+Class
<input type="text"/>	<input type="text"/>

(now go to 43)

+ See chapter 19 for defined terms.

All entities

Fees

43 Payment method (tick one)

Cheque attached

Electronic payment made

Note: Payment may be made electronically if Appendix 3B is given to ASX electronically at the same time.

Periodic payment as agreed with the home branch has been arranged

Note: Arrangements can be made for employee incentive schemes that involve frequent issues of securities.

Quotation agreement

1 +Quotation of our additional +securities is in ASX's absolute discretion. ASX may quote the +securities on any conditions it decides.

2 We warrant the following to ASX.

- The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
- There is no reason why those +securities should not be granted +quotation.
- An offer of the +securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any +securities to be quoted and that no-one has any right to return any +securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the +securities be quoted.
- We warrant that if confirmation is required under section 1017F of the Corporations Act in relation to the +securities to be quoted, it has been provided at the time that we request that the +securities be quoted.
- If we are a trust, we warrant that no person has the right to return the +securities to be quoted under section 1019B of the Corporations Act at the time that we request that the +securities be quoted.

+ See chapter 19 for defined terms.

Appendix 3B
New issue announcement

- 3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.

- 4 We give ASX the information and documents required by this form. If any information or document not available now, will give it to ASX before *quotation of the *securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here:

Print name: Stephen Birrell
Company Secretary

Date: 22 September 2006

+ See chapter 19 for defined terms.

22 September 2006

Securities and Exchange Commission
Judiciary Plaza,
450 Fifth Street,
Washington DC 20549

SEC
Mail Processing
Section

APR 28 2008

Washington, DC
105

Re: Bionomics Limited - File number 82-34682

Please see attached provided pursuant to Section 12g3-2(b) file number 82-34682.

Yours sincerely



Stephen Birrell
CFO & Company Secretary

Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 1/7/96. Origin: Appendix 5. Amended 1/7/98, 1/9/99, 1/7/2000, 30/9/2001, 11/3/2002.

Name of entity

BIONOMICS LIMITED

ABN

53 075 582 740

We (the entity) give ASX the following information.

Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

1 +Class of +securities issued or to be issued

UNLISTED OPTIONS

2 Number of +securities issued or to be issued (if known) or maximum number which may be issued

EIGHT HUNDRED AND TWENTY SIX THOUSAND TWO HUNDRED AND FIFTY (826,250)

3 Principal terms of the +securities (eg, if options, exercise price and expiry date; if partly paid +securities, the amount outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion)

EXERCISE PRICE: 22 cents (set in accordance with the terms of the Bionomics ESOP).
EXERCISE PERIOD: 1/5th each year commencing from the first anniversary of acceptance of the Invitation relating to those Options and ending at 5.00pm (Adelaide time) on the date that is 5 years after the commencement of the period.
EXPIRY DATE: 5 years after the date on which the options became exercisable.

+ See chapter 19 for defined terms.

Appendix 3B
New issue announcement

4 Do the ⁺securities rank equally in all respects from the date of allotment with an existing ⁺class of quoted ⁺securities?

YES

If the additional securities do not rank equally, please state:

- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

5 Issue price or consideration

NIL

6 Purpose of the issue
 (If issued as consideration for the acquisition of assets, clearly identify those assets)

OPTIONS ISSUED TO STAFF UNDER THE BIONOMICS LIMITED EMPLOYEE SHARE OPTION PLAN.

7 Dates of entering ⁺securities into uncertificated holdings or despatch of certificates

21 SEPTEMBER 2006

	Number	⁺ Class
8 Number and ⁺ class of all ⁺ securities quoted on ASX (including the securities in clause 2 if applicable)	154,918,432	ORDINARY SHARES
	9,795,822	OPTIONS EXP. 31-07-07
	31,535,063	OPTIONS EXP. 31-01-09

⁺ See chapter 19 for defined terms.

	Number	+Class
9 Number and +class of all +securities not quoted on ASX (including the securities in clause 2 if applicable)	11,996,583	OPTIONS
10 Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)	NOT APPLICABLE – EARLY STAGE BIOTECHNOLOGY COMPANY	

Part 2 - Bonus issue or pro rata issue

- | | |
|--|--|
| 11 Is security holder approval required? | |
| 12 Is the issue renounceable or non-renounceable? | |
| 13 Ratio in which the +securities will be offered | |
| 14 +Class of +securities to which the offer relates | |
| 15 +Record date to determine entitlements | |
| 16 Will holdings on different registers (or subregisters) be aggregated for calculating entitlements? | |
| 17 Policy for deciding entitlements in relation to fractions | |
| 18 Names of countries in which the entity has +security holders who will not be sent new issue documents

<small>Note: Security holders must be told how their entitlements are to be dealt with.
Cross reference: rule 7.7.</small> | |
| 19 Closing date for receipt of acceptances or renunciations | |

+ See chapter 19 for defined terms.

Appendix 3B
New issue announcement

- | | | |
|----|---|--|
| 20 | Names of any underwriters | |
| 21 | Amount of any underwriting fee or commission | |
| 22 | Names of any brokers to the issue | |
| 23 | Fee or commission payable to the broker to the issue | |
| 24 | Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of +security holders | |
| 25 | If the issue is contingent on +security holders' approval, the date of the meeting | |
| 26 | Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent to persons entitled | |
| 27 | If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders | |
| 28 | Date rights trading will begin (if applicable) | |
| 29 | Date rights trading will end (if applicable) | |
| 30 | How do +security holders sell their entitlements <i>in full</i> through a broker? | |
| 31 | How do +security holders sell <i>part</i> of their entitlements through a broker and accept for the balance? | |

+ See chapter 19 for defined terms.

- 32 How do ⁺security holders dispose of their entitlements (except by sale through a broker)?
- 33 ⁺Despatch date

Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities

34 Type of securities
(tick one)

(a) Securities described in Part I

(b) All other securities

Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

Entities that have ticked box 34(a)

Additional securities forming a new class of securities

(If the additional securities do not form a new class, go to 43)

Tick to indicate you are providing the information or documents

- 35 If the ⁺securities are ⁺equity securities, the names of the 20 largest holders of the additional ⁺securities, and the number and percentage of additional ⁺securities held by those holders
- 36 If the ⁺securities are ⁺equity securities, a distribution schedule of the additional ⁺securities setting out the number of holders in the categories
1 - 1,000
1,001 - 5,000
5,001 - 10,000
10,001 - 100,000
100,001 and over
- 37 A copy of any trust deed for the additional ⁺securities

(now go to 43)

⁺ See chapter 19 for defined terms.

Entities that have ticked box 34(b)

38 Number of securities for which
 *quotation is sought

39 Class of *securities for which
 quotation is sought

40 Do the *securities rank equally in all
 respects from the date of allotment
 with an existing *class of quoted
 *securities?

If the additional securities do not
 rank equally, please state:

- the date from which they do
- the extent to which they
 participate for the next dividend,
 (in the case of a trust,
 distribution) or interest payment
- the extent to which they do not
 rank equally, other than in
 relation to the next dividend,
 distribution or interest payment

41 Reason for request for quotation
 now

Example: In the case of restricted securities, end of
 restriction period

(if issued upon conversion of
 another security, clearly identify that
 other security)

	Number	*Class
42	Number and *class of all *securities quoted on ASX (<i>including</i> the securities in clause 38)	<input style="width: 100%; height: 60px;" type="text"/>

(now go to 43)

+ See chapter 19 for defined terms.

All entities

Fees

43 Payment method (tick one)

Cheque attached

Electronic payment made

Note: Payment may be made electronically if Appendix 3B is given to ASX electronically at the same time.

Periodic payment as agreed with the home branch has been arranged

Note: Arrangements can be made for employee incentive schemes that involve frequent issues of securities.

Quotation agreement

1 +Quotation of our additional +securities is in ASX's absolute discretion. ASX may quote the +securities on any conditions it decides.

2 We warrant the following to ASX.

- The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
- There is no reason why those +securities should not be granted +quotation.
- An offer of the +securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any +securities to be quoted and that no-one has any right to return any +securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the +securities be quoted.
- We warrant that if confirmation is required under section 1017F of the Corporations Act in relation to the +securities to be quoted, it has been provided at the time that we request that the +securities be quoted.
- If we are a trust, we warrant that no person has the right to return the +securities to be quoted under section 1019B of the Corporations Act at the time that we request that the +securities be quoted.

+ See chapter 19 for defined terms.

Appendix 3B
New issue announcement

- 3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.

- 4 We give ASX the information and documents required by this form. If any information or document not available now, will give it to ASX before +quotation of the +securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here:

Print name: Stephen Birrell
Company Secretary

Date: 22 September 2006

+ See chapter 19 for defined terms.

11 October 2006

Securities and Exchange Commission
Judiciary Plaza,
450 Fifth Street,
Washington DC 20549

SEC
Mail Processing
Section
APR 28 2008
Washington, DC
105

Re: Bionomics Limited - File number 82-34682

Please see attached provided pursuant to Section 12g3-2(b) file number 82-34682.

Yours sincerely



**Stephen Birrell
CFO & Company Secretary**

Asia Pacific Life Sciences Forum

Bionomics Limited

October 2006

Revolutionary therapies for cancer and
Central Nervous System (CNS)
diseases

Safe Harbor Statement

Factors Affecting Future Performance

This presentation contains "forward-looking" statements within the meaning of the United States' Private Securities Litigation Reform Act of 1995. Any statements contained in this presentation that relate to prospective events or developments, including, without limitation, statements made regarding Bionomics' development candidate BNC105, its drug discovery programs and pending patent applications are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions are intended to identify forward-looking statements.

There are a number of important factors that could cause actual results or events to differ materially from those indicated by these forward-looking statements, including risks related to our available funds or existing funding arrangements, a downturn in our customers' markets, our failure to introduce new products or technologies in a timely manner, regulatory changes, risks related to our international operations, our inability to integrate acquired businesses and technologies into our existing business and to our competitive advantages, as well as other factors. Results of studies performed on competitors products may vary from those reported when tested in different settings.

Subject to the requirements of any applicable legislation or the listing rules of any stock exchange on which our securities are quoted, we disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this presentation.

2

Bionomics Overview

- Strategy to partner early
 - Early value creation, reduced risk and strong deal making potential
- 4 drug development programs
 - Cancer – flagship product BNC105 for treatment of solid cancers
 - Central Nervous System (CNS) diseases
 - Epilepsy
 - Anxiety
 - Multiple Sclerosis
- Income from genomics licensing deals – with more to come
 - Genmab: Antibody-based cancer drugs
 - LabCorp: Childhood epilepsy tests
 - Athena: Childhood epilepsy test
- Drug discovery technology - MultiCore® for the generation of multiple new product opportunities

3

FY05/06 Milestone Achievements

- all targets achieved on time

- ✓ Acquisition of Iliad Chemicals – July 05
- ✓ LabCorp epilepsy diagnostics deal – Nov 05
- ✓ Genmab antibody target licensing deal - Feb 06
- ✓ BNC105 anti-cancer candidate selection – April 06
- ✓ \$3.7m Federal Govt grant for BNC105 development – April 06
- ✓ Faster than expected progress in epilepsy and anxiety projects

4

What sets Bionomics apart?

- ✓ **Strength of pipeline**
 - Multiple shots on goal to support "partner early-partner often strategy"
- ✓ **Platform technologies – foundation for future products with strong IP**
 - MultiCore® – chemistry for good drugs, from Iliad acquisition
 - Strong CNS capability – from Neurofit acquisition
 - Angene® – cancer drug discovery
 - Genomics – over 300 genes within Bionomics patent portfolio
- ✓ **Validated through commercial, revenue generating partnerships**
 - Successfully commercialized genomics assets
- ✓ **A company of substance**
 - Vertically integrated with people experienced in the disciplines of biotech management, drug discovery and development
- ✓ **Low cash burn**
 - Successfully integrated 3 companies into 1 capable of greater value creation whilst maintaining low level of cash burn


5

Cancer: BNC105

- Powerful vascular disrupting agent (VDA)
- Shuts down cancer blood vessels
- Does not shut down normal blood vessels
- Next generation treatment for cancer



Tumour



Tumour + BNC105

6


BNC105: Radically outperforms its competitors

- Several VDAs are in development worldwide
- Most advanced is Oxigene's CA4P (Phase III trials)
- BNC105 outperforms CA4P
 - ✓ Safer: 20 times broader therapeutic window (ratio of effective dose to dose at which side-effects are seen)
 - ✓ More effective in enhancing the efficacy of chemotherapies

7

BNC105: Radically outperforms its competitors

Tumor Growth relative to Day 1



CA4P + 5-Fluorouracil

8

BNC105: Significant market potential

- Estimated market for VDAs is US\$5 billion pa
(ASInsights 2003)
- Anticipated market share: 10-20%
- Indicative value of BNC105 with Phase I/II data (available late 2008)
 - License fees: US\$ 50m to US\$100m
 - Royalty: 5 -10% (US\$15m to US\$100m pa)

9

BNC105: Milestones and Strategy

Milestones

- | | |
|--|----------|
| □ Manufacture completed | Q4, 2006 |
| □ Pivotal toxicology completed | Q2, 2007 |
| □ IND submission | Q3, 2007 |
| □ Approval for Phase I/II clinical trial | Q4, 2007 |
| □ Phase I/II completed | Q3, 2008 |

Strategy

- Licensing activity in progress
- Evaluate offers vs. net benefit from further development

10



Epilepsy

- Need for drugs that stop seizures without side-effects
 - └ Current market dominated by old, off-patent medicines
 - └ 30% of patients can't control seizures with any medication
 - └ Other 70% tolerate occasional seizures and significant side effects
- Bionomics GABA-A receptor modulators prevent seizures
 - └ More effective in seizure models than marketed drugs
- No significant side-effects noted
 - └ Class of molecules have a long history of safe pharmaceutical use

11

Epilepsy Market opportunity

- 2.5 million patients in US (4.1 million in seven major pharma markets)
- Anti-epileptic sales: >\$7 billion in US alone
- Example: Keppra
 - Launched 1999
 - Approved for adjunct treatment



Keppra's success illustrates the potential for an effective treatment

12

Epilepsy: Milestones and Strategy

Milestones

- Patents filed on compounds Q1, 2007
- Drug chosen for clinical development Q2, 2007
- Seek approval for Phase I clinical trial Q1, 2008
- Phase I clinical trial completed Q2, 2008

Strategy

- Licensing activity in progress
- Evaluate offers vs. net benefit from further development
- Consider progress of other assets

13

Anxiety

- Anxiety drugs have been amongst the biggest blockbusters e.g. Valium, Prozac
 - 19 million patients in US alone
 - US \$5-12 billion pa worldwide
- Most have major drawbacks or side-effects
- Market need for safe, fast acting, non-sedating drug

- Bionomics drugs are effective and non-sedating
 - In vivo activity in rodents without sedation
 - Class of molecules have long history of safe pharmaceutical use
 - Properties indicate once per day, oral administration

14

Anxiety: Milestones and Strategy

Milestones

- Patents filed on compounds Q4, 2006
- Drug chosen for clinical development Q2, 2007
- Seek approval for Phase I clinical trial Q3, 2008
- Phase I clinical trial completed Q4, 2008

Strategy

- Licensing activity in progress
- Evaluate offers vs. net benefit from further development
- Consider progress of other assets

15

Multiple Sclerosis

- Current treatments only partly effective and most have major side-effects
- Latest drugs are injected
- Market need for safe, effective, oral drug
- Estimated market is US\$2 billion pa

- Bionomics drugs target new mechanism of action
 - Highly selective and potent = effective without side-effects
 - Properties consistent with orally acting drug
 - Potential for extension of indication to other inflammatory disorders

16

Multiple Sclerosis: Milestones & Strategy

Milestones

- Patents filed on compounds Q1, 2007
- Drug chosen for clinical development Q4, 2007
- Seek approval for Phase I clinical trial Q4, 2008
- Phase I clinical trial completed Q3, 2009

Strategy

- Licensing activity in progress
- Evaluate offers vs. net benefit from further development
- Consider progress of other assets


17

MultiCore® Platform

- Proprietary, diversity-orientated chemistry
- Rapid synthesis of diverse and complex molecular structures
- Drug discovery tool
 - Enriched libraries
 - More effective optimisation of hits
- Scalable synthesis and analoging of natural products
- New drugs from old drugs, with improved properties

18

Bionomics' Partnerships



19

Executive Management

Our management team has a long track record of accomplishment and commercial success

- | | | |
|---|--|---|
|  | Dr. Deborah Rathjen
<i>Managing Director and CEO</i> | Inventor of Peptech TNF technology, responsible for significant licensing deals |
|  | Dr. Alex Szabo
<i>VP, Business Development</i> | Affymetrix, Beckman Coulter, Pharmacia Biotech |
|  | Dr. Bernard Flynn
<i>VP, Chemistry</i> | Inventor of MultiCore [®] chemistry platform |
|  | Dr. Gabriel Kremmidiotis
<i>VP, Cancer Research</i> | Founding Bionomics scientist
Creator of Angene [®] platform |
|  | Dr. Ian Street
<i>VP, Drug Discovery</i> | Merck, Amrad, Walter and Eliza Hall Institute |
|  | Dr. Frank Sams-Dodd
<i>GM, Neurofit, VP Preclinical Research</i> | Former Director of CNS Preclinical Research, Boehringer-Ingelheim |
|  | Stephen Birrell
<i>CFO, Company Secretary</i> | 20 years experience in financial services, high-tech, luxury goods |

20

Financials FY05/06

- Revenues: A\$2.26 m
 - Grant income: A\$2.30 m
 - Net cash burn: A\$4.20 m
 - Cash at 30/6/06: A\$4.73 m
-
- A\$5 million capital raising completed in September 2006

21

Bionomics Investment Fundamentals

- **4 potential blockbuster drugs in development**
 - Valuable drug portfolio
 - Licensing and development strategy to maximise value
 - Solid news flow anticipated
- **Income from existing licensed assets, with more deals in the pipeline**
 - Licensing deal with Genmab with blockbuster potential
 - All deals upfront payments, milestones and royalties with no further cost to BNO
- **New product opportunities will be created**
 - Core capabilities and proprietary technologies, including MultiCore® chemistry platform to rapidly generate valuable product opportunities to drive partner early – partner often strategy
- **Proven management team**
 - Deal track record
 - Experienced drug development team

22

Bionomics Limited

For further information contact:

Dr Deborah Rathjen, CEO & Managing Director

Phone: +61 8 8354 6101

Mobile: +61 8 418 160 425

**Revolutionary therapies for cancer and Central
Nervous System (CNS) diseases**

www.bionomics.com.au

23 November 2006

Securities and Exchange Commission
Judiciary Plaza,
450 Fifth Street,
Washington DC 20549

SEC
Mail Processing
Section
APR 28 2008
Washington, DC
105

Re: Bionomics Limited - File number 82-34682

Please see attached provided pursuant to Section 12g3-2(b) file number 82-34682.

Yours sincerely



Stephen Birrell
CFO & Company Secretary



NOTICE UNDER SECTION 708A(6) OF THE CORPORATIONS ACT

On 16 November 2006, Bionomics Limited (ASX:BNO) ABN 53 075 582 740 (**Company**) issued 19,142,855 fully paid ordinary shares by way of a private placement (**Issue**) that may be subject to a subsequent offer for sale. The Company relies on section 708A(5) of the Corporations Act (**Act**) in relation to the Issue.

In accordance with section 708A(6) the following information is provided:

- a) this notice is given within 5 business days after the day of the Issue;
- b) the Issue is without disclosure to investors under Part 6D.2 of the Act;
- c) this notice is given under section 708A(5)(e) of the Act;
- d) as at the date of this notice, the Company has complied with the provisions of Chapter 2M of the Act as they apply to the Company and section 674 of the Act;
- e) as at the date of this notice, there is no excluded information to be provided in accordance with section 708A(7) and (8) of the Act.

All questions in respect of the announcement should be directed to Stephen Birrell on (08) 8354-6104.

Yours faithfully,

A handwritten signature in black ink, appearing to be "S. Birrell", written over a horizontal line.

Stephen Birrell
Company Secretary